Nebenwirkungen · Trulicity
Trulicity 0.75 mg solution for injection in pre-filled pen Trulicity 1.5 mg solution for injection in pre-filled pen Trulicity 3 mg solution for injection in pre-filled pen Trulicity 4.5 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 10
HOS-130072 · Präparat HOS-096833
Gastrointestinal adverse reactions Cumulative reporting of gastrointestinal events up to 104 weeks with dulaglutide 0.75 mg and 1.5 mg, respectively, included nausea (12.9 % and 21.2 %), diarrhoea (10.7 % and 13.7 %) and vomiting (6.9 % and 11.5 %). These were typically mild or moderate in severity and were reported to peak during the first 2 weeks of treatment and rapidly declined over the next 4 weeks, after which the rate remained relatively constant.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-30T14:51:00Z · SHA-256 8f7c34e4753bded4db7c0494f49b503f91f5736e3b7e360143648c1ad38b32e3 · Passage ab84df85b0a2fe216e8ccf8cb0f2a8963105df4c8225dcb52e09f86a353b9c1d · Zeichen 6398–6856 im Abschnitt